A new trading day began on Monday, with Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) stock price up 0.14% from the previous day of trading, before settling in for the closing price of $50.99. RARE’s price has ranged from $34.06 to $60.37 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 63.06% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged 22.42%. With a float of $86.21 million, this company’s outstanding shares have now reached $92.17 million.
In an organization with 1276 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 83.47%, operating margin of -114.04%, and the pretax margin is -121.93%.
Ultragenyx Pharmaceutical Inc (RARE) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Ultragenyx Pharmaceutical Inc is 6.46%, while institutional ownership is 96.88%. The most recent insider transaction that took place on Oct 10 ’24, was worth 393,853. In this transaction Chief Financial Officer of this company sold 7,465 shares at a rate of $52.76, taking the stock ownership to the 92,301 shares. Before that another transaction happened on Sep 03 ’24, when Company’s President & CEO sold 20,000 for $55.85, making the entire transaction worth $1,117,000. This insider now owns 2,223,985 shares in total.
Ultragenyx Pharmaceutical Inc (RARE) Latest Financial update
In its latest quarterly report, released on 6/30/2024, the company reported earnings of -2.23 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.36 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 22.42% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 37.90% during the next five years compared to -15.75% drop over the previous five years of trading.
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) Trading Performance Indicators
Here are Ultragenyx Pharmaceutical Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.39. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.78.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -7.29, a number that is poised to hit -1.48 in the next quarter and is forecasted to reach -5.28 in one year’s time.
Technical Analysis of Ultragenyx Pharmaceutical Inc (RARE)
Let’s dig in a bit further. During the last 5-days, its volume was 1.03 million. That was better than the volume of 0.77 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 8.95%. Additionally, its Average True Range was 1.61.
During the past 100 days, Ultragenyx Pharmaceutical Inc’s (RARE) raw stochastic average was set at 60.13%, which indicates a significant increase from 14.96% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 17.40% in the past 14 days, which was lower than the 40.50% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $55.58, while its 200-day Moving Average is $47.90. However, in the short run, Ultragenyx Pharmaceutical Inc’s stock first resistance to watch stands at $51.93. Second resistance stands at $52.79. The third major resistance level sits at $53.84. If the price goes on to break the first support level at $50.02, it is likely to go to the next support level at $48.97. The third support level lies at $48.11 if the price breaches the second support level.
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) Key Stats
With a market capitalization of 4.71 billion, the company has a total of 92,165K Shares Outstanding. Currently, annual sales are 434,250 K while annual income is -606,640 K. The company’s previous quarter sales were 147,030 K while its latest quarter income was -131,600 K.
